BCAX
Bicara Therapeutics Inc. Common Stock NASDAQ Listed Sep 13, 2024$19.78
After hrs
$19.78
+0.00%
Mkt Cap $1.3B
52w Low $10.48
45.3% of range
52w High $30.99
50d MA $24.92
200d MA $21.31
P/E (TTM)
—
EV/EBITDA
—
P/B
2.7x
Debt/Equity
0.0x
ROE
-34.4%
P/FCF
-10.5x
RSI (14)
28.40
ATR (14)
$1.20
Beta
-1.23
50d MA
$24.92
200d MA
$21.31
Avg Volume
555.2K
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
CIK (SEC)
Phone
617-468-4219
116 Huntington Avenue · Boston, MA 02116 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | AMC | -0.82 | -0.82 | -0.0% | 23.76 | +1.0% | +3.7% | -4.1% | +2.8% | +2.7% | -0.1% | — |
| May 11, 2026 | AMC | -0.64 | -0.93 | -45.3% | 22.92 | +0.0% | -2.4% | -6.2% | -1.6% | -2.0% | -4.6% | — |
| Mar 26, 2026 | AMC | -0.72 | -0.68 | +5.6% | 18.92 | -1.4% | -2.9% | +3.6% | +4.5% | +3.1% | +4.7% | — |
| Nov 10, 2025 | AMC | -0.55 | -0.67 | -21.8% | 13.93 | -0.9% | +5.7% | +1.2% | -4.4% | +3.6% | +1.8% | — |
| Aug 12, 2025 | AMC | -0.54 | -0.50 | +7.4% | 10.47 | +1.5% | +8.2% | +0.7% | +2.0% | -1.5% | +0.3% | — |
| May 13, 2025 | AMC | -0.40 | -0.68 | -70.0% | 13.04 | +1.2% | +5.1% | +5.6% | +0.0% | +5.1% | -1.1% | — |
| Mar 27, 2025 | AMC | -0.31 | -0.39 | -25.8% | 13.40 | -0.1% | +0.0% | -2.8% | -2.8% | +4.7% | -10.8% | — |
| Nov 12, 2024 | AMC | -0.46 | -1.60 | -247.8% | 22.35 | +0.0% | -1.6% | +1.1% | -9.3% | -4.8% | +0.6% | — |
| Sep 13, 2024 | AMC | — | -0.45 | — | 23.41 | -4.6% | +8.5% | +6.5% | -5.0% | -4.4% | +4.1% | — |
| Jun 30, 2024 | AMC | — | -0.27 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2023 | AMC | — | -0.23 | — | — | — | — | — | — | — | — | — |
| Sep 30, 2023 | AMC | — | -0.42 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2023 | AMC | — | -0.15 | — | — | — | — | — | — | — | — | — |
| Mar 31, 2023 | AMC | — | -0.15 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 19 | BMO Capital Markets | Initiates | Outperform | $35 | $24.92 | $26.09 | +4.7% | +3.8% | -5.7% | -2.0% | -1.3% | +4.2% |
| May 11 | Guggenheim | Initiates | Buy | $42 | $22.58 | $22.49 | -0.4% | +1.5% | -2.4% | -6.2% | -1.6% | -2.0% |
| Mar 31 | Citizens | Maintains | Market Outperform → Market Outperform | — | $19.04 | $19.41 | +1.9% | +4.5% | +3.1% | +4.7% | -2.9% | +2.1% |
| Mar 31 | Goldman Sachs | Maintains | Neutral → Neutral | — | $19.04 | $19.41 | +1.9% | +4.5% | +3.1% | +4.7% | -2.9% | +2.1% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.04 | $19.41 | +1.9% | +4.5% | +3.1% | +4.7% | -2.9% | +2.1% |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $19.04 | $19.41 | +1.9% | +4.5% | +3.1% | +4.7% | -2.9% | +2.1% |
| Mar 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $19.04 | $19.41 | +1.9% | +4.5% | +3.1% | +4.7% | -2.9% | +2.1% |
| Jan 13 | Wedbush | Maintains | Outperform → Outperform | — | $17.43 | $17.34 | -0.5% | +0.6% | +2.8% | -7.4% | +0.4% | -0.2% |
| Nov 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.93 | $13.80 | -0.9% | +5.7% | +1.2% | -4.4% | +3.6% | +1.8% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.63 | $11.63 | +0.0% | +1.8% | -4.4% | +6.4% | -0.2% | -0.9% |
| May 23 | Wells Fargo | Upgrade | Underweight → Equal Weight | — | $15.66 | $11.65 | -25.6% | -40.8% | +7.7% | -5.2% | -0.2% | -2.0% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.47 | $13.77 | -4.8% | +0.0% | +5.1% | -1.1% | -3.0% | +7.3% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.57 | $10.24 | -3.1% | -10.0% | -1.5% | +11.0% | -2.4% | +6.1% |
| Mar 13 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $13.01 | $12.90 | -0.8% | +2.6% | -7.0% | +8.7% | -7.9% | -0.3% |
| Feb 12 | Wedbush | Maintains | Outperform → Outperform | — | $13.02 | $12.82 | -1.5% | +1.5% | -0.8% | +2.7% | -2.9% | +0.5% |
| Jan 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.61 | $12.03 | +3.6% | +0.3% | +2.8% | -1.8% | +9.8% | -2.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Cohlhepp RyanDir/Off | President, COO & Interim CEO | Sell | 3,442 | $23.43 | $81K | 181,641 | -1.26% | +2.68% |
| Sep 8, 2026 | Cohlhepp RyanDir/Off | President, COO & Interim CEO | Sell | 14,058 | $22.77 | $320K | 185,083 | -1.26% | +2.68% |
| Aug 10, 2026 | Cohlhepp RyanDir/Off | President and COO | Sell | 18,750 | $27.98 | $525K | 181,641 | -4.06% | +3.77% |
| Aug 10, 2026 | Mazumdar ClaireDir/Off | Chief Executive Officer | Sell | 10,000 | $27.98 | $280K | 362,152 | -4.06% | +3.77% |
| Aug 10, 2026 | Hyep IvanOff | Chief Financial Officer | Sell | 12,500 | $27.97 | $350K | 129,855 | -4.06% | +3.77% |
| Jul 10, 2026 | Mazumdar ClaireDir/Off | Chief Executive Officer | Sell | 28 | $29.68 | $831 | 362,152 | +0.07% | +3.68% |
| Jul 10, 2026 | Mazumdar ClaireDir/Off | Chief Executive Officer | Sell | 9,972 | $28.42 | $283K | 362,180 | +0.07% | +3.68% |
| Jul 9, 2026 | Cohlhepp RyanDir/Off | President and COO | Sell | 536 | $29.00 | $16K | 181,641 | -2.63% | +0.58% |
| Jul 8, 2026 | Hyep IvanOff | Chief Financial Officer | Sell | 830 | $30.31 | $25K | 129,855 | -2.63% | +0.58% |
| Jul 8, 2026 | Hyep IvanOff | Chief Financial Officer | Sell | 4,413 | $29.82 | $132K | 130,685 | -2.63% | +0.58% |
| Jul 8, 2026 | Hyep IvanOff | Chief Financial Officer | Sell | 22,757 | $28.60 | $651K | 135,098 | -2.63% | +0.58% |
| Jul 8, 2026 | Cohlhepp RyanDir/Off | President and COO | Sell | 1,075 | $30.35 | $33K | 182,177 | -2.63% | +0.58% |
| Jul 8, 2026 | Cohlhepp RyanDir/Off | President and COO | Sell | 4,306 | $29.80 | $128K | 183,252 | -2.63% | +0.58% |
| Jul 8, 2026 | Cohlhepp RyanDir/Off | President and COO | Sell | 22,833 | $28.76 | $657K | 187,558 | -2.63% | +0.58% |
| May 21, 2026 | Hyep IvanOff | Chief Financial Officer | Sell | 9,200 | $20.42 | $188K | 145,355 | -1.82% | -4.75% |
| May 18, 2026 | Mazumdar ClaireDir/Off | Chief Executive Officer | Sell | 2,978 | $20.35 | $61K | 362,152 | +2.01% | +0.79% |
| May 18, 2026 | Mazumdar ClaireDir/Off | Chief Executive Officer | Sell | 12,022 | $19.96 | $240K | 365,130 | +2.01% | +0.79% |
| May 15, 2026 | Cohlhepp RyanDir/Off | President and COO | Sell | 4,500 | $20.29 | $91K | 191,641 | +3.84% | +1.38% |
| May 15, 2026 | Cohlhepp RyanDir/Off | President and COO | Sell | 8,000 | $20.29 | $162K | 196,141 | +3.84% | +1.38% |
| Apr 27, 2026 | Raben DavidOff | Chief Medical Officer | Sell | 5,500 | $22.88 | $126K | 55,286 | -2.92% | -0.22% |
8-K · 1.01
!! High
Bicara Therapeutics Inc. -- 8-K 1.01: Material Agreement
Aug 25
8-K · 2.02
!! High
Bicara Therapeutics Inc. -- 8-K 2.02: Earnings Results
Aug 11
8-K · 5.02
!!! Very High
Bicara Therapeutics Inc. -- 8-K 5.02: Executive Change
Jul 28
8-K
Bicara Therapeutics Inc. -- 8-K Filing
Jun 10
8-K · 2.02
!! High
Bicara Therapeutics Inc. -- 8-K 2.02: Earnings Results
May 11
8-K
Unknown — 8-K Filing
Bicara advanced its lead cancer drug ficerafusp alfa into Phase 3 with an optimized dosing schedule, potentially improving patient compliance and commercial viability; interim data in mid-2027 will determine success probability.
Mar 30
8-K
Bicara Therapeutics Inc. -- 8-K Filing
Bicara Therapeutics issued pre-funded warrants exercisable at $0.0001 per share, allowing immediate cashless exercise, providing investors with nearly certain conversion rights to common stock.
Feb 26
8-K · 8.01
!! High
Bicara Therapeutics Inc. -- 8-K 8.01: Material Event / Announcement
Bicara Therapeutics announced that ficerafusp alfa at 2000mg every-two-weeks showed strong efficacy in head-and-neck cancer patients, supporting potential for less frequent dosing schedules.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Siren, L.l.c. | 5,602,970 | $166M | New | Jun 2026 |
| 2 | Deep Track Capital, Lp | 4,100,000 | $122M | New | Jun 2026 |
| 3 | Blackrock, Inc. | 3,848,090 | $114M | New | Jun 2026 |
| 4 | Red Tree Management, Llc | 3,163,517 | $94M | New | Jun 2026 |
| 5 | Janus Henderson Group Plc | 3,339,218 | $66M | New | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 2,216,639 | $66M | Added | Jun 2026 |
| 7 | Royalty Pharma Sub-Manager, Llc | 2,388,150 | $61M | — | Jun 2026 |
| 8 | Fmr Llc | 2,100,929 | $42M | Reduced | Mar 2026 |
| 9 | Franklin Resources Inc | 1,621,643 | $32M | — | Mar 2026 |
| 10 | Jones Hill Capital Lp | 892,621 | $27M | Reduced | Jun 2026 |
| 11 | Palo Alto Investors Lp | 550,408 | $16M | New | Jun 2026 |
| 12 | D. E. Shaw & Co., Inc. | 498,193 | $15M | Added | Jun 2026 |
| 13 | Nan Fung Trinity (Hk) Ltd | 427,885 | $13M | — | Jun 2026 |
| 14 | Citadel Advisors Llc | 422,284 | $13M | Reduced | Jun 2026 |
| 15 | Vanguard Portfolio Management Llc | 418,912 | $12M | Added | Jun 2026 |
| 16 | Aisling Capital Management Lp | 568,919 | $11M | — | Mar 2026 |
| 17 | Walleye Capital Llc | 353,226 | $10M | Added | Jun 2026 |
| 18 | Ensign Peak Advisors, Inc | 401,444 | $8M | — | Mar 2026 |
| 19 | Millennium Management Llc | 262,254 | $8M | Added | Jun 2026 |
| 20 | Td Asset Management Inc | 261,118 | $8M | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$1.30B
Enterprise Value
$706.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.07x
P/B
2.69x
P/S
—
P/FCF
-10.46x
EV/EBITDA
—
Shares Out
54.7M
Financials (TTM)
Revenue
$0
Net Income
-$185.4M
EBITDA
-$184.4M
Free Cash Flow
-$107.1M
Op Cash Flow
-$106.8M
EPS Basic
$-2.52
EPS Diluted
$-3.10
EPS Forward
$-2.73
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$431.0M
Total Liab.
$29.5M
Total Equity
$401.5M
Cash
$414.8M
LT Debt
$593K
Book Value/Sh
$7.34
Debt/Equity
0.00x
Current Ratio
14.58
Quick Ratio
14.58
Returns & Growth
ROE
-34.4%
ROA
-32.0%
ROIC
-38.6%
Rev Growth YoY
+0.0%
EPS Growth YoY
-101.6%
Price Returns
2W
-13.3%
1M
-13.1%
3M
-20.1%
6M
+12.8%
12M
+83.1%
Technicals
52W High
$30.99
52W Low
$10.48
50d MA
$24.92
200d MA
$21.31
RSI (14)
28.40
ATR (14)
$1.20
Beta
-1.23
Avg Volume
555K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$20.00
High
$28.00
Low
$14.00
Median
$18.00
Data updated apr 24, 2026 8:50pm
· Source: financialmodelingprep.com